BUE:PFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BUE:PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pfizer Inc BUE:PFE
Pfizer BUE:PFE +0.63% 58 Beneish M-Score is -2.32 as of Jun. 24, 2026. GuruFocus rates BUE:PFE with a GF Score™ of 58/100 and a GF Value™ of ARS10,141.47 (Fairly Valued). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Pfizer ranks worse than 63.34% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Pfizer's Beneish M-Score or its related term are showing as below:
During the past 13 years, the highest Beneish M-Score of Pfizer was -1.92. The lowest was -2.72. And the median was -2.42.
The historical data trend for Pfizer's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Pfizer Annual Data | |||||||||||||||||||||
| Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||||
| Beneish M-Score | Get a 7-Day Free Trial |
|
|
-2.06 | -2.30 | -2.30 | -2.65 | -2.31 | |||||||||||||
| Pfizer Quarterly Data | ||||||||||||||||||||
| Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | |
| Beneish M-Score | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
-2.61 | -2.52 | -2.43 | -2.31 | -2.32 | ||
For the Drug Manufacturers - General subindustry, Pfizer's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Pfizer's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Pfizer for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 1.0287 | + | 0.528 * 0.9849 | + | 0.404 * 1.0129 | + | 0.892 * 1.3985 | + | 0.115 * 1.0397 | |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI | |||||||
| - | 0.172 * 0.9508 | + | 4.679 * 0.010004 | - | 0.327 * 1.0118 | |||||||
| = | -2.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Mar26) TTM: | Last Year (Mar25) TTM: |
| Total Receivables was ARS22,613,818 Mil. Revenue was 20204641.558 + 25483792.166 + 22616338.546 + 17396528.174 = ARS85,701,300 Mil. Gross Profit was 15243667.977 + 17831542.22 + 16950710.804 + 12911161.12 = ARS62,937,082 Mil. Total Current Assets was ARS59,875,651 Mil. Total Assets was ARS290,300,849 Mil. Property, Plant and Equipment(Net PPE) was ARS27,128,751 Mil. Depreciation, Depletion and Amortization(DDA) was ARS8,890,302 Mil. Selling, General, & Admin. Expense(SGA) was ARS18,562,330 Mil. Total Current Liabilities was ARS48,026,922 Mil. Long-Term Debt & Capital Lease Obligation was ARS83,670,986 Mil. Net Income was 3757084.558 + -2392053.853 + 4808721.916 + 3454848.631 = ARS9,628,601 Mil. Non Operating Income was -760645.329 + -6945374.809 + -2280102.823 + -268314.705 = ARS-10,254,438 Mil. Cash Flow from Operations was 3656410.912 + 7762563.109 + 6250931.087 + -690969.726 = ARS16,978,935 Mil. |
Total Receivables was ARS15,718,715 Mil. Revenue was 14620696.595 + 17941640.179 + 16824799.761 + 11894926.33 = ARS61,282,063 Mil. Gross Profit was 11587821.509 + 11973550.12 + 11822318.48 + 8939776.372 = ARS44,323,466 Mil. Total Current Assets was ARS48,889,520 Mil. Total Assets was ARS221,765,532 Mil. Property, Plant and Equipment(Net PPE) was ARS19,558,580 Mil. Depreciation, Depletion and Amortization(DDA) was ARS6,751,996 Mil. Selling, General, & Admin. Expense(SGA) was ARS13,959,893 Mil. Total Current Liabilities was ARS38,859,178 Mil. Long-Term Debt & Capital Lease Obligation was ARS60,572,219 Mil. |
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (22613817.849 / 85701300.444) | / | (15718714.641 / 61282062.865) | |
| = | 0.263868 | / | 0.256498 | |
| = | 1.0287 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) | |
| = | (44323466.481 / 61282062.865) | / | (62937082.121 / 85701300.444) | |
| = | 0.72327 | / | 0.734377 | |
| = | 0.9849 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (59875651.268 + 27128751.247) / 290300849.21) | / | (1 - (48889519.983 + 19558579.689) / 221765531.998) | |
| = | 0.700296 | / | 0.691349 | |
| = | 1.0129 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 | |
| = | 85701300.444 | / | 61282062.865 | |
| = | 1.3985 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (6751995.688 / (6751995.688 + 19558579.689)) | / | (8890301.826 / (8890301.826 + 27128751.247)) | |
| = | 0.256627 | / | 0.246822 | |
| = | 1.0397 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (18562329.795 / 85701300.444) | / | (13959893.316 / 61282062.865) | |
| = | 0.216593 | / | 0.227797 | |
| = | 0.9508 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((83670986.219 + 48026922.37) / 290300849.21) | / | ((60572218.779 + 38859178.439) / 221765531.998) | |
| = | 0.45366 | / | 0.448363 | |
| = | 1.0118 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t | |
| = | (9628601.252 - -10254437.666 | - | 16978935.382) | / | 290300849.21 | |
| = | 0.010004 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Pfizer has a M-score of -2.04 suggests that the company is unlikely to be a manipulator.
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of ARS9,620.00 is trading 5.1% below its estimated GF Value™ of ARS10,141.47. GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for BUE:PFE:
No single metric tells the full story. See the BUE:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.